Robin T. Zon, M.D., F.A.C.P. hails from western New York. She graduated Magna Cum Laude with a B.S. in Chemistry, from the University of Detroit. Prior to pursuing a career in medicine, she worked as a pharmaceutical research investigator and manager of medical diagnostic product research and development. Dr. Zon earned her medical degree from Indiana University School of Medicine, completed her residency at St. Vincent Hospital and Health Care Center in Indianapolis, Indiana and a fellowship in medical oncology and hematology at Indiana University. Dr. Zon has been certified in internal medicine and medical oncology and currently serves as Director of Research at Memorial Hospital in South Bend, Indiana. Dr. Zon's professional interests include clinical research, as she is the principal investigator for Cancer Control Studies with the Northern Indiana Cancer Research Consortium (NICRC), is currently Vice-Chair of the Hoosier Oncology Group, and has served as co-chair on the American Society of Clinical Oncology (ASCO) Clinical Trials Workshop committee. Dr. Zon is active as community co-chair of breast cancer research studies within ECOG. Her community service includes Board membership with RiverBend Cancer Services of St. Joseph County and the Center for Hospice and Palliative Care.
Jo Anne ZUJEWSKI , MD (USA)
Jo Anne Zujewski, MD is the Head - Breast Cancer Therapeutics, in the Clinical Investigation Branch of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. In this role, she is the scientific liaison and disease expert for breast cancer clinical trials sponsored by the CTEP program of the NCI.
Dr. Zujewski's research activities include the clinical development of targeted agents for the treatment of breast cancer. She was the founding chairperson of the Breast Cancer Faculty steering committee at NCI and a member of the planning committee for the NIH Consensus conference for the adjuvant treatment of breast cancer, Preoperative Therapy in Invasive Breast Cancer scheduled, and the state of the science meeting for Ductal Carcinoma in situ. She has an interest in global breast health and has served as an expert medical consultant to several international initiatives in breast cancer. She is the author of numerous publications in breast cancer treatment and prevention.
A native of Chicago, Illinois, she received her Bachelor of Science in Medical Technology from Marquette University and her Masters of Administrative Science from Johns Hopkins Evening College. Dr. Zujewski earned her M.D. at the University of Minnesota. She completed her internal medicine residency at University of Washington and her medical oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center. Dr. Zujewski joined the staff at the National Cancer Institute in 1993. She spent her first 10 years at the NCI in the intramural research program evaluating targeted therapeutics for the prevention and treatment of breast cancer. In November, 2004, Dr. Zujewski joined the Cancer Therapy Evaluation Program (CTEP) as the Head - Breast Cancer Therapeutics of the Clinical Investigations Branch.
Alexandru Eniu , MD (Romania)
Dr. Alexandru Eniu is a medical oncologist at the Breast Cancer Center of the National Cancer Institute Ion Chiricuta in Cluj-Napoca, Romania. His training as a M.D. and a medical oncologist was completed in Romania. He also obtained his PhD degree from the University Of Medicine Iuliu Hatieganu. He was awarded several scholarships that allowed him to learn and practice medical oncology in France and in Italy at the European Institute of Oncology. More recently he was awarded a Mayo Foundation Visiting Clinician Scholarship at the Mayo Breast Cancer Clinic in Jacksonville, Florida. Apart from his national credentials, he holds the European Certification in Medical Oncology after successfully sustaining the European Society of Medical Oncology (ESMO) Certification Examination in 2000 and being Re-Certified in 2005. He is an active member of the American Society of Clinical Oncology (ASCO) and of the European Society for Medical Oncology (ESMO). He served as a member of the ASCO Cancer Education SubCommittee for Breast Cancer, and the ASCO Task Force for the International Clinical Trials Workshop. He is also a member of the ESMO Ethics Committee. He is member in the editorial board of The Lancet Oncology, Romanian version, MEMO - Magazine of European Medical Oncology, Journal of the Romanian Society for Radiotherapy & Oncology and the Journal of the Balkan Union of Oncology. His interest in improving the outcome of patients with breast cancer led to his recruitment as a core team member at the Breast Cancer Centre in Cluj, where he holds a position as Head of the Day Hospital Unit. He participated in the process of developing national guidelines for the management of cancer patients. Dr. Eniu’s background of training and working in various environments enabled him to better capture the differences that exist when practicing oncology in countries with high versus moderate/low level of resources. His continuous search for better ways of delivering care to breast cancer patients made him be part of the Breast Health Global Initiative since 2002, serving as the Co-Chair of the Treatment and Allocation of resources Panel. He is the author of several publications in peer reviewed journals and he also delivered talks on numerous occasions in Europe and in the U.S.. Currently he is continuing his clinical practice devoted to the care of breast cancer patients and his clinical research interest, being an investigator for several international clinical trials.
2. NCI - USA faculty
Joe B. HARFORD, MD (USA)
Director, Office of International Affairs, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Dr. Joe Harford received a Ph.D. in Biochemistry from the University of Maryland Medical School and conducted basic research in molecular biology and cell biology. Dr. Harford has published over 100 scientific papers. Dr. Harford is one of the founding editors for Current Protocols in Cell Biology.
In 1993, Dr. Harford became the chief scientist for RiboGene, Inc., a biotechnology company where he managed four drug discovery programs in infectious diseases. From 1996 to1999, Dr. Harford served as Chairman of the Scientific Advisory Board of RiboGene, Inc, and served in a similar capacity for SynerGene Therapeutics, Inc., an early-stage biopharmaceutical company that focuses on molecular therapeutics for cancer. Dr. Harford is a co-inventor on two issued U.S. patents related to drug discovery. In 1996, Dr. Harford returned to the NIH where he served as Associate Director of the NCI and Chief of Staff of the Office of the Director.
In July 2002, Dr. Joe Harford was named Director of the Office of International Affairs of the National Cancer Institute. In this capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreign cancer research institutions and other foreign entities. Dr. Harford serves as the Chair of the Strategic Advisory Group of the Ireland-Northern Ireland-NCI Cancer Consortium and as NCI liaison to the Middle East Cancer Consortium, the US-Japan Cooperative Cancer Research Program, the African Organization for Research and Training in Cancer, the American-Russian Cancer Alliance, and the International Network for Cancer Treatment and Research. Dr. Harford has represented the United States to the Governing Council of the WHO’s International Agency for Research on Cancer and represented NIH for two years as a member of the Board of Trustees of the Human Frontier Science Program, an international non-governmental, nonprofit association devoted to the promotion of basic research. In July 2006, Dr. Harford was named as Strategic Leader for Knowledge Transfer by the International Union Against Cancer (UICC). In 2008, UICC altered its committee structure, and Dr. Harford was named to the UICC Board of Directors (NCI Liaison), the Solidarity Fund Taskforce, the Childhood Cancer Taskforce, and the Strategic Coordinating Committee. Dr. Harford has been appointed by the Irish Minister for Health and Children to the National Expert Group on Cancer Biobanking.
In 2007, Dr. Harford was recognized by the Arab Medical Association Against Cancer with an award, the citation os which reads "In recognition for his significant contribution to enhance the status of cancer care and cancer research in the region and for his unwavering efforts to support needed infrastructure and create opportunities in cancer education, training and capacity building to help cancer patients and their families throughout the Arab world."
3. SEMCO faculty
Sherif OMAR (Egypt)
President of Education and Research Committee at Egyptian Parliment,
Ex. Dean of National Cancer Institute (NCI), Cairo University, Egypt
Professor of Surgery, National Cancer Institute. President of Board of Trustees of Egyptian Foundation for Cancer Research and member of Governing Council of INCTR Egypt